Bulk Inquiry
Cediranib
- AZD2171
- Soluble in DMSO
- MF: C25H27FN4O3
- MW: 450.51
Description
More Information
| Parent CAS No. | 288383-20-0 |
|---|---|
| Chemical Name | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline |
| SMILES | C1(OC)C=C2C(OC3C=CC4NC(C)=CC=4C=3F)=NC=NC2=CC=1OCCCN1CCCC1 |
| MFCD | MFCD09954115 |
| InChi | InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 |
| InChiKey | XXJWYDDUDKYVKI-UHFFFAOYSA-N |
| CID | 9933475 |
| Short Description | VEGFR inhibitor |
References
- SR Wedge et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65 (10), 4389–400.
- G Goss et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine. Eur. J. Cancer 2008, 45, 782.
- P Nikolinakos & JV Heymach. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 2008, 3 (6 Suppl 2): S131–4.
- CA Heckman et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68(12), 4754-4762.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1357 | SD 169 |
From $66.00 |
| 1358 | BIRB 796 |
From $71.50 |
| 1363 | SB 203580 |
From $104.50 |
| 1364 | SB 202190 |
From $104.50 |
| 1365 | PD169316 |
From $104.50 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1667 | SU 5402 |
From $66.00 |
